Technical Analysis for GMDA - Gamida Cell Ltd.

Grade Last Price % Change Price Change
D 0.37 15.77% 0.05
GMDA closed up 15.77 percent on Monday, March 18, 2024, on 2.6 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 25
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Fell Below 50 DMA Bearish 13.85%
180 Bearish Setup Bearish Swing Setup 13.85%
Crossed Above 50 DMA Bullish 5.53%
Stochastic Buy Signal Bullish 5.53%

   Recent Intraday Alerts

Alert Time
Rose Above Upper Bollinger Band about 13 hours ago
Upper Bollinger Band Resistance about 13 hours ago
Up 2 ATRs about 14 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Possible Pocket Pivot about 15 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Cyclacel Rare Serious Hematologic Diseases

Is GMDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

S

SociableGnat503 8 months ago

Any thoughts on this one? It's insane of how much this has bled over the past several weeks. 

0 Reply
T

TraderMike 8 months ago

My only thoughts are this seems to be a small biotech doing what small biotechs do.  These things are incredibly news driven, especially the clinical stage ones.

1 Reply
S

SociableGnat503 7 months ago

They have an earnings call on Monday and onboarding and sales will likely determine where it goes in the future.  

0 Reply
S

SociableGnat503 7 months ago

Looks like it has a bullish pattern although this thing has been manipulated for so long that it's impossible to ascertain of how reliable the signal is.  Hoping for the best on this one! 

0 Reply

View full discussion...

Indicators

Indicator Value
52 Week High 2.51
52 Week Low 0.2184
Average Volume 2,922,550
200-Day Moving Average 0.89
50-Day Moving Average 0.35
20-Day Moving Average 0.35
10-Day Moving Average 0.34
Average True Range 0.04
RSI (14) 53.70
ADX 13.37
+DI 26.23
-DI 17.18
Chandelier Exit (Long, 3 ATRs) 0.32
Chandelier Exit (Short, 3 ATRs) 0.42
Upper Bollinger Bands 0.40
Lower Bollinger Band 0.31
Percent B (%b) 0.69
BandWidth 23.77
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0015
Fundamentals Value
Market Cap 49.08 Million
Num Shares 133 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 75.50
Price-to-Book 132.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.47
Resistance 3 (R3) 0.47 0.44 0.45
Resistance 2 (R2) 0.44 0.41 0.44 0.45
Resistance 1 (R1) 0.40 0.40 0.42 0.40 0.44
Pivot Point 0.37 0.37 0.38 0.37 0.37
Support 1 (S1) 0.34 0.35 0.35 0.34 0.30
Support 2 (S2) 0.31 0.33 0.30 0.29
Support 3 (S3) 0.27 0.31 0.29
Support 4 (S4) 0.27